Investors pocket $761M in deal betting on Biogen’s BG-12

Like a lot of biotech investors, Royalty Pharma sees blockbuster potential in Biogen Idec's ($BIIB) experimental BG-12. The New York-based buyer of royalty interests in biopharma products has laid dow…
Read the full story: News